SCHEMBL6923671

SCHEMBL6923671

NCCOc1cccc2c1c1ccccc1n2Cc1cccc(F)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.43
MAPT P10636 3/20 0.43
ALDH1A1 P00352 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
IDO1 P14902 2/20 0.42
HTR1B P28222 1/20 0.42
LMNA P02545 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTR6 P50406 1/20 0.40
HTT P42858 2/20 0.40
TSHR P16473 1/20 0.40
GLA P06280 1/20 0.39
AURKA O14965 1/20 0.39
RPS6KB1 P23443 1/20 0.39
CYP19A1 P11511 1/20 0.39
TAAR1 Q96RJ0 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2B Q13224 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6921144 0.88 CYP19A1 (0.53) ALDH1A1HTR1BTDP1SMN1; SMN2HTR6
SCHEMBL6925585 0.86 MEN1 (0.47) MAPTALDH1A1HTR1BTDP1HTR6
SCHEMBL6925182 0.86 HTR1B (0.42) MAPTHTR1BSMN1; SMN2HTR6HTT
SCHEMBL6921602 0.84 ABCG2 (0.48) POLBMAPTALDH1A1HTR1BTAAR1
SCHEMBL6926713 0.82 ALDH1A1 (0.47) MAPTALDH1A1HTR1BLMNASMN1; SMN2
SCHEMBL6924330 0.81 P2RX4 (0.52) ALDH1A1HTR1BTDP1SMN1; SMN2HTR6
SCHEMBL6924311 0.81 P2RX4 (0.43) POLBMAPTHTR1BHTR6GRIN1
SCHEMBL6921541 0.80 HTR6 (0.47) MAPTHTR1BSMN1; SMN2HTR6CYP19A1
SCHEMBL6923328 0.78 PLA2G2A (0.45) POLBMAPTALDH1A1LMNATDP1
SCHEMBL6921601 0.76 PLA2G2A (0.47) POLBMAPTALDH1A1HTR6HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514968-B1 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising PHARMACIA & UPJOHN COMPANY 2003-02-04 US claimed
EP-1210329-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-06-05 EP claimed
WO-2001017963-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2001-03-15 WO claimed
US-6514968-B1 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising PHARMACIA & UPJOHN COMPANY 2003-02-04 US disclosed
EP-1210329-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-06-05 EP disclosed
WO-2001017963-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2001-03-15 WO disclosed